Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Iovance Biotherapeutics, Inc. (IOVA : NSDQ)

• Company Description    Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells. Number of Employees: 319

• Price / Volume Information    Yesterday's Closing Price: $15.43 Daily Weekly Monthly 20 Day Moving Average: 1,900,694 shares Shares Outstanding: 157.17 (millions) Market Capitalization: $2,425.10 (millions) Beta: 0.86 52 Week High: $28.00 52 Week Low: $11.91 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -3.98% 8.13% 12 Week 3.91% 14.22% Year To Date -19.17% -4.31%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 825 INDUSTRIAL ROAD SUITE 400 - SAN CARLOS,CA 94070 USA ph: 650-260-7120 fax: - sara.pellegrino@iovance.com http://www.iovance.com

• General Corporate Information    Officers Frederick G. Vogt - Interim Chief Executive Officer and President; and Jean-Marc Bellemin - Chief Financial Officer and Treasurer Merrill A. McPeak - Director Michael Weiser - Director Ryan D. Maynard - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 462260100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 157.17 Most Recent Split Date: 9.00 (0.01:1) Beta: 0.86 Market Capitalization: $2,425.10 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.61 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.45 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.39 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -13.73% vs. Previous Quarter: 7.94% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -54.79 12/31/21 - -50.48 09/30/21 - -45.34 ROA 03/31/22 - -45.37 12/31/21 - -42.65 09/30/21 - -38.91 Current Ratio 03/31/22 - 6.36 12/31/21 - 5.69 09/30/21 - 9.00 Quick Ratio 03/31/22 - 6.36 12/31/21 - 5.69 09/30/21 - 9.00 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 3.51 12/31/21 - 3.96 09/30/21 - 4.45 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.18 12/31/21 - 0.16 09/30/21 - 0.14

Powered by Zacks Investment Research ©